Tesamorelin
Egrifta · TH9507 · Stabilized GHRH(1-44)
Think of it as a gym buddy for your metabolism.
Tesamorelin is like a personal trainer for your body's growth hormone. It encourages your pituitary gland to release more of this hormone naturally, which can help trim down the deep belly fat that tends to stick around, especially in certain health conditions. Think of it as giving your body a little nudge to work more efficiently.
This peptide doesn't just jack up hormone levels; it keeps the rhythm of release more natural, like a steady heartbeat rather than a constant buzz. Research has shown it can lead to a significant reduction in visceral fat, which is the stubborn stuff around your organs, and may also tweak some metabolic markers in a positive direction. But remember, its main gig is for a specific medical scenario, so don't expect it to be the magic fix for everyone.
Who it's for
- Health enthusiasts curious about growth hormone dynamics
- Individuals focused on reducing deep abdominal fat
- People interested in exploring metabolic health tweaks
- Science-minded folks intrigued by hormone regulation
Probably not for you if…
- Those looking for a general weight loss solution
- Individuals without specific medical guidance
- People uncomfortable with research-backed but niche applications
Editorial summary for research context · Not medical advice
Mechanism of Action
Tesamorelin is a synthetic 44-amino-acid GHRH analog with a trans-3-hexenoic acid modification at the N-terminus that confers resistance to enzymatic degradation. It binds pituitary GHRH receptors to stimulate endogenous GH release, preserving pulsatility while sustaining elevated GH and IGF-1 over the dosing interval. It is FDA-approved as Egrifta for the reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy — the only GHRH analog currently holding an FDA approval. Use outside this indication is off-label; research-grade material is not FDA-approved for general human use.
Researched Benefits
Visceral adipose reduction
Two randomized Phase 3 trials in HIV-lipodystrophy patients showed significant reductions in visceral adipose tissue (VAT) on CT imaging versus placebo over 26 weeks.
- [Falutz et al. 2007]
- [Stanley et al. 2014]
IGF-1 elevation with preserved pulsatility
Unlike long-acting DAC-bound analogs, Tesamorelin sustains IGF-1 increases while keeping the GH secretory pattern more physiologic.
Metabolic profile research
Published data show improvements in triglycerides and adiponectin in the FDA-approval population; effects on glucose tolerance require monitoring.
Research Protocols
The following dosing ranges have appeared in published research protocols. Presented for informational purposes only — not a recommendation for human use.
FDA-approved indication (HIV lipodystrophy)
- Dosage
- 2 mg
- Frequency
- once daily
- Timing
- evening, subcutaneous abdominal injection
- Cycle
- 26 weeks
FDA-approved labeling: 2mg subcutaneous daily for HIV-associated excess visceral adipose tissue. Prescription required. Effects plateau around 6 months.
Reported Side Effects
- Injection-site reactions (erythema, pruritus, pain)
- Arthralgia and peripheral edema
- Paresthesia
- Possible reduction in insulin sensitivity / increased fasting glucose
- Headache
- Rare hypersensitivity reactions
Contraindications
- Active malignancy
- Pregnancy and lactation
- Hypothalamic-pituitary axis disruption (hypophysectomy, radiation, tumor)
- Untreated or uncontrolled diabetes
- Known hypersensitivity to tesamorelin or mannitol
Stacking Partners
Peptides commonly paired with Tesamorelin in published research and protocol write-ups.
Vendor Pricing
Stacked earns a commission on purchases via these links. It does not influence our Trust Scores.
Gear + Companions
Reconstitution supplies and research-backed supplement companions for Tesamorelin. Editorial picks only — we earn a commission through Amazon on the click, no sponsorship.
Gear you'll need
· Reconstitution + storage essentialsBacteriostatic Water 30mL (0.9% Benzyl Alcohol)
Empower Pharmacy / generic medical supply
Reconstitutes every lyophilized peptide. 28-day viability refrigerated.
Insulin Syringes 31G × 5/16" × 0.5mL (100 count)
EasyTouch
31G × 0.5mL insulin syringes — the default size for sub-0.25mL peptide doses.
Alcohol Prep Pads (Sterile, 200 count)
Dynarex
Sterile 70% IPA prep pads — one per vial stopper + one per injection site.
1-Quart Sharps Disposal Container
BD / Becton Dickinson
FDA-cleared sharps container — pharmacies won't accept improvised disposal.
Stacks well with
· Supplement companions — independent evidence, not sponsoredCreatine Monohydrate Powder 1kg
BulkSupplements
Creatine + GH-axis peptides increase lean-mass signaling via different pathways (IGF-1 + phosphocreatine replenishment). Most-studied stack in the literature.
Whey Protein Isolate 5 lb (Grass-Fed, Unflavored)
NAKED Nutrition
Growth-hormone-axis research is substrate-limited — without adequate protein intake the signaling can't translate to tissue.
As an Amazon Associate we earn from qualifying purchases · Disclosed per FTC guidelines
Top Videos
Curated from YouTube — refreshed weekly. Stacked doesn't host or endorse external content.
7:15Doctor Explains Your RISK of Cancer From Popular Peptides
This Is Not Covered - Dr. Ashley Froese
173.1K views · 7:15 · 5 months ago
4:50Doctor Reviews TOP Peptides For Fat Loss, Energy, & Endurance
This Is Not Covered - Dr. Ashley Froese
162.2K views · 4:50 · 8 months ago
10:47Why This Peptide Is Taking Over Bodybuilding
Joey Thurman
104.6K views · 10:47 · 4 years ago
8:13How Much Tesamorelin Should I Take A Day
Regan Archibald
88.9K views · 8:13 · 8 months ago
4:05My Results After 12 Weeks: Tesamorelin/Ipamorelin Peptides (Fat loss, Muscle, Cognitive Function)
Living Youthful
61.1K views · 4:05 · 1 year ago
Research Papers
Metabolic effects of a growth hormone-releasing factor in patients with HIV
Falutz J, et al. · New England Journal of Medicine · 2007
PubMed 17804844 →Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation
Stanley TL, et al. · JAMA · 2014
PubMed 25247519 →